BCDA
BioCardia, Inc.·Healthcare
0.90
1.218%(−0.01)
Market OpenLast Updated: — ET
52W L: $0.8452W H: $2.45
BCDA NEWS
globenewswire.com
6d ago
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development – Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) preliminary open label cohort at EuroPCR, a leading interventional cardiovascular medicine conference held in Paris.
seekingalpha.com
May 15
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
globenewswire.com
May 15
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management's formal remarks, there will be a question-and-answer session.
globenewswire.com
May 11
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
SUNNYVALE, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, May 15, 2026 at 4:30 PM EDT.
globenewswire.com
May 11
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026
SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the first quarter of 2026 by conference call on Friday, May 15, 2026 at 4:30 PM EDT. Following management's formal remarks, there will be a question-and-answer session.
globenewswire.com
May 8
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways
SUNNYVALE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the outcome of its Pre-Submission Meeting with FDA on the Helix Transendocardial Delivery Catheter System (Helix).
